Abstract
Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Optimal Management of Hypertension in patients with Ischemic Heart Disease
Volume: 7 Issue: 3
Author(s): Debabrata Mukherjee and Charles L. Campbell
Affiliation:
Abstract: Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Export Options
About this article
Cite this article as:
Mukherjee Debabrata and Campbell L. Charles, Optimal Management of Hypertension in patients with Ischemic Heart Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (3) . https://dx.doi.org/10.2174/187152509789105435
DOI https://dx.doi.org/10.2174/187152509789105435 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Potential Anticancer Agents. I. Synthesis of Isoxazole Moiety Containing Quinazoline Derivatives and Preliminarily in vitro Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Association between Paraoxonase 1(PON1) Gene Polymorphisms and PON1 Enzyme Activity in Indian Patients with Coronary Artery Disease (CAD)
Current Pharmacogenomics and Personalized Medicine The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses Directing Cardiomyogenic Differentiation and Transdifferentiation By Ectopic Gene Expression – Direct Transition Or Reprogramming Detour?
Current Gene Therapy Clinical Assessment of Central Blood Pressure
Current Hypertension Reviews CCR2 Antagonists
Current Topics in Medicinal Chemistry Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Cystatin C, Adipokines and Cardiovascular Risk in HIV Infected Patients
Current HIV Research Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome
Current Vascular Pharmacology Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics F508del-CFTR Rescue: A Matter of Cell Stress Response
Current Pharmaceutical Design Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K. Anagnostopoulou, D.P. Mikhailidis and G. Kolovou)]
Current Drug Targets